Bicyclically Substituted Uracils and the Use Thereof
Bayer Pharma Aktiengesellschaft
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 4 of these applications claim priority to application PCT/EP2013/059286, filed May 3, 2013. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 9,481,672 | Bicyclically Substituted Uracils and the Use Thereof In force · High confidence | Bayer Pharma Aktiengesellschaft | In force | High confidence | ||
| US 9,949,977 | Bicyclically Substituted Uracils and the Use Thereof In force · Medium confidence | Bayer Pharma Aktiengesellschaft | In force | Medium confidence | ||
| US 9,949,978 | Bicyclically Substituted Uracils and the Use Thereof In force · Medium confidence | Bayer Pharma Aktiengesellschaft | In force | Medium confidence | ||
| US 10,300,062 | Bicyclically Substituted Uracils and the Use Thereof In force · Low confidence | Bayer Pharma Aktiengesellschaft | In force | Low confidence | ||
| Application 16/373,487 | Bicyclically Substituted Uracils and the Use Thereof Abandoned Abandoned Jul 30, 2020 | Bayer Pharma Aktiengesellschaft | Abandoned | Abandoned Jul 30, 2020 |
5 of 5 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
4 of these are in force and held by Bayer Pharma Aktiengesellschaft.
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.